Srini Akkaraju

Srini Akkaraju, MD/PhD, is the Founder and Managing General Partner of Samsara BioCapital, a Palo Alto-based venture capital firm he founded in 2016 to translate cutting-edge biology into transformative therapeutics. With a Stanford MD/PhD in Immunology and a computer science foundation from Rice University, Akkaraju has spent over 25 years at the intersection of science and capital - from corporate development at Genentech to partnership roles at J.P. Morgan Partners, Panorama Capital, New Leaf Venture Partners, and Sofinnova Ventures. Samsara has built a portfolio of 93+ companies with 32 IPO exits, backing breakthroughs in immunotherapy, cell therapy, kidney disease, and gene therapy. His conviction-driven approach is evident in moves like a $19M personal stake in Scholar Rock, and his belief that biotech is entering an 'unbelievable innovation cycle' over the next two to three decades.